Atyr Pharma Inc (ATYR) Stock Price & Analysis
Atyr Pharma Inc (ATYR) fell 4.98% to USD 0.47 as of July 25, 2026 at 06:39 UTC, according to Nexqual real-time market data.
ATYR last closed at USD 0.5; the session ranged USD 0.47–0.51 on volume of 820,045 shares. Market capitalization is $46.41M, with a 52-week range of USD 0.4–7.29 (NCM). Source: Nexqual, July 25, 2026 at 06:39 UTC.
Key Statistics (as of July 25, 2026 at 06:39 UTC)
| Price | USD 0.47 |
|---|---|
| Change | ▼ 4.98% (down) |
| Previous Close | USD 0.5 |
| Open | USD 0.5 |
| Day Range | USD 0.47 – 0.51 |
| 52-Week Range | USD 0.4 – 7.29 |
| Volume | 820,045 shares |
| Market Cap | $46.41M |
| Exchange | NCM |
Technical Analysis (ATYR)
Nexqual's technical model rates ATYR "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.07 (neutral) |
| vs SMA50 | Below (USD 0.51) |
| MACD | -0.02 (negative) |
Analyst Ratings (ATYR)
Wall Street analysts rate ATYR "Buy" based on 7 analysts, with a mean price target of USD 2.86 (range USD 1–7), per Nexqual as of July 25, 2026 at 06:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 2.86 |
| High Target | USD 7 |
| Low Target | USD 1 |
| Buy / Hold / Sell | 4 / 5 / 0 |
Earnings (ATYR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.13 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.11 vs est -0.14 ▲ beat |
| 2025-12-31 | USD -0.14 vs est -0.18 ▲ beat |
| 2025-09-30 | USD -0.26 vs est -0.18 ▼ miss |
| 2025-06-30 | USD -0.22 vs est -0.18 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Financials & Fundamentals (ATYR)
| Total Revenue | $190,000 |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | -38573.68% |
| Profit Margin | +0.00% |
| ROE | -105.63% |
| Debt / Equity | 20.26 |
| Current Ratio | 5.78 |
| Total Cash | $66.51M |
| Total Debt | $11.70M |
| Free Cash Flow | $-32.65M |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Financial Health Score (ATYR)
Nexqual rates Atyr Pharma Inc's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:39 UTC.
| Growth | Critical — Revenue -19% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $67M cash vs $12M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$33M, burning cash |
| Efficiency | Critical — ROE -106%, ROA -51.8% |
Ownership (ATYR)
| Insider Ownership | +2.45% |
|---|---|
| Institutional Ownership | +46.34% |
| Shares Outstanding | 98.05M |
| Float | 95.51M |
| Short % of Float | +9.73% |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Leadership (ATYR)
Atyr Pharma Inc is led by Sanjay S. Shukla M.D., M.S. (age 53), President, CEO & Director, per Nexqual as of July 25, 2026 at 06:39 UTC.
| President, CEO & Director | Sanjay S. Shukla M.D., M.S. (age 53) |
|---|---|
| Chief Financial Officer | Jill M. Broadfoot (age 63) |
| Director of Investor Relations & Corporate Communications | Ashlee Dunston |
| Vice President of Corporate Development | Peter Villiger |
| Vice President of Research | Leslie Nangle |
Major Backers & Investors (ATYR)
Notable institutional backers of Atyr Pharma Inc include Federated Hermes, Inc., FMR, LLC, Fidelity, according to Nexqual as of July 25, 2026 at 06:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Federated Hermes, Inc. | 21.32% |
| FMR, LLC | 15% |
| Fidelity | 7.6% |
| UBS Group AG | 3.94% |
| GSA Capital Partners LLP | 1.72% |
| Millennium Management | 1.67% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.4% |
| Vanguard Group | 7.62% |
| Geode Capital | 2.43% |
| State Street | 1.79% |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
From Atyr Pharma Inc's Latest SEC 10-K Filing (filed 2026-03-05)
Key Strengths & Strategy (as disclosed to the SEC)
- aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
- Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD.
- The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATCH | AtlasClear Holdings, Inc. | USD 0.18 | ▼ 16.98% |
| LRMR | Larimar Therapeutics, Inc. | USD 4 | ▼ 0.5% |
| IXHL | Incannex Healthcare Inc. | USD 2.95 | ▼ 5.45% |
| CGTX | Cognition Therapeutics, Inc. | USD 0.92 | ▼ 4.42% |
| RZLT | Rezolute, Inc. | USD 4.99 | ▼ 0.2% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:39 UTC. This page is informational and not investment advice.